LOS ANGELES, Aug. 21, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Capricor Therapeutics, Inc. ("Capricor" or "the Company") (NASDAQ: CAPR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
LOS ANGELES, Aug. 21, 2026 /PRNewswire/ -- Schall, Brown & Schwartz LLP ("SBS"), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Capricor Therapeutics, Inc. ("Capricor" or "the Company") (NASDAQ: CAPR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
From Optimism to Disillusionment: Capricor Therapeutics investors watched sentiment collapse from confidence in an August 22, 2026 approval date to a 78.7% share decline after FDA briefing documents allegedly surfaced undisclosed statistical analysis plan changes.
NEW YORK, Aug. 20, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Capricor Therapeutics, Inc. ("Capricor" or the "Company") (NASDAQ: CAPR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
SAN FRANCISCO, Aug. 20, 2026 /PRNewswire/ -- National investor rights law firm Hagens Berman highlights developments surrounding Capricor Therapeutics, Inc. (NASDAQ: CAPR). Following Capricor's recent Q2 2026 earnings release and conference call—notable for an omission of management Q&A with analysts—the company is facing uncertainty amid an active securities fraud class action.
LOS ANGELES, Aug. 19, 2026 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with losses related to Capricor Therapeutics, Inc. (CAPR) have opportunity to lead the securities fraud class action lawsuit.
From Optimism to Disillusionment: Capricor Therapeutics investors watched sentiment collapse from confidence in an August 22, 2026 approval date to a 78.7% share decline after FDA briefing documents allegedly surfaced undisclosed statistical analysis plan changes.
NEW YORK, Aug. 19, 2026 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Capricor Therapeutics, Inc. (NASDAQ: CAPR) between December 17, 2025 and July 26, 2026, inclusive (the "Class Period"), of the important September 28, 2026 lead plaintiff deadline.
NEW YORK, Aug. 18, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Capricor Therapeutics, Inc. (NASDAQ: CAPR).
Capricor Therapeutics, Inc. has been sued for securities fraud over alleged misstatements about Deramiocel and the integrity of the clinical data supporting its Biologics License Application leading to a 64% stock drop.
